Overview

DP303c in Patients With HER2-positive Advanced Breast Cancer

Status:
Not yet recruiting
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
This is a study of DP303c in patients with HER2-positive advanced breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Treatments:
Capecitabine
Trastuzumab
Vinorelbine